腫瘤科
止血的管理和優化
抗纖溶藥物
Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. （開啟新視窗）
來源: Cancer 2013;119(21):3784-7.
檢索: PubMed 23921838
DOI碼: 10.1002/cncr.28253
Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. （開啟新視窗）
來源: Lancet 1989;334(8655):122-4.
檢索: PubMed 2567893
Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. （開啟新視窗）
來源: Eur J Haematol 1990;45(2):86-9.
檢索: PubMed 2209824
Fibrinolytic inhibitors for cancer-associated bleeding problems. （開啟新視窗）
來源: J Pain Symptom Manage 1997;13(1):20-4.
檢索: PubMed 9029858
Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. （開啟新視窗）
來源: J Clin Oncol 2015;33(15):1674-9.
檢索: PubMed 25870085
DOI碼: 10.1200/JCO.2014.57.9912
Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. （開啟新視窗）
來源: Scand J Haematol 1985;35(5):497-500.
檢索: PubMed 4089529
Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. （開啟新視窗）
來源: Cancer 2006;107(1):136-40.
檢索: PubMed 16708357
DOI碼: 10.1002/cncr.21958
Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. （開啟新視窗）
來源: Hematol Oncol 2016;34(3):147-53.
檢索: PubMed 25641349
DOI碼: 10.1002/hon.2189
Tranexamic acid to treat life-threatening hemorrhage in prostate cancer associated disseminated intravascular coagulation with excessive fibrinolysis. （開啟新視窗）
來源: Cureus 2015;7(12):e428.
檢索: PubMed 26848417
DOI碼: 10.7759/cureus.428
A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. （開啟新視窗）
來源: Leuk Lymphoma 1995;19(1-2):141-4.
檢索: PubMed 8574160
DOI碼: 10.3109/10428199509059668
Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. （開啟新視窗）
來源: Hematol Oncol 2008;26(4):241-6.
檢索: PubMed 18613223
DOI碼: 10.1002/hon.867
重組活化凝血因子VII（rFVIIa）
Use of Novoseven for arsenic trioxide-induced bleeding in PML. （開啟新視窗）
來源: Am J Hematol 2006;81(9):720.
檢索: PubMed 16804937
DOI碼: 10.1002/ajh.20713
Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. （開啟新視窗）
來源: Clin Appl Thromb Hemost 2005;11(4):401-10.
檢索: PubMed 16244765
The off-label use of recombinant FVIIa in the treatment of a patient with T-cell non-Hodgkin lymphoma who developed intra-abdominal and intra-pleural hemorrhages followed by high-dose methotreaxate therapy. （開啟新視窗）
來源: Eur J Clin Med Oncol 2011;3(5):1-4.
檢索: EMBASE 2012295551
The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. （開啟新視窗）
來源: Bone Marrow Transplant 2007;39(12):729-35.
檢索: PubMed 17417659
DOI碼: 10.1038/sj.bmt.1705670
Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. （開啟新視窗）
來源: Am J Hematol 2002;69(3):219-22.
檢索: PubMed 11891811
Use of recombinant activated factor VII in a Jehovah's Witness patient. （開啟新視窗）
來源: Am J Emerg Med 2007;25(9):1085.e1-2.
檢索: PubMed 18022514
DOI碼: 10.1016/j.ajem.2007.03.007
Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. （開啟新視窗）
來源: Haemostasis 1996;26 Suppl 1:159-64.
檢索: PubMed 8904193
Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. （開啟新視窗）
來源: Med Oncol 2010;27(1):16-9.
檢索: PubMed 19137431
DOI碼: 10.1007/s12032-008-9163-y
Recombinant factor VIIa for bleeding in refractory thrombocytopenia. （開啟新視窗）
來源: Thromb Haemost 2000;83(4):634-5.
檢索: PubMed 10780334
Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. （開啟新視窗）
來源: Eur J Haematol 2004;72(6):455-6.
檢索: PubMed 15128428
DOI碼: 10.1111/j.1600-0609.2004.00237.x
凝血因子濃縮劑
Management of bleeding complications of hematologic malignancies. （開啟新視窗）
來源: Semin Thromb Hemost 2007;33(4):427-34.
檢索: PubMed 17525900
DOI碼: 10.1055/s-2007-976178
Vitamin K deficiency in cancer patients referred to a hospital palliative care team with bleeding and the impact of vitamin K replacement on laboratory indicators of vitamin K status. （開啟新視窗）
來源: Int J Lab Hematol 2013;35(4):457-9.
檢索: PubMed 23216984
DOI碼: 10.1111/ijlh.12035
Management of bleeding in patients with advanced cancer. （開啟新視窗）
來源: Oncologist 2004;9(5):561-70.
檢索: PubMed 15477642
DOI碼: 10.1634/theoncologist.9-5-561
去氨加壓素
Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. （開啟新視窗）
來源: Haematologica 1997;82(5):584-7.
檢索: PubMed 9407726
Desmopressin and other synthetic vasopressin analogues in cancer treatment. （開啟新視窗）
來源: Bull Cancer 2006;93(2):E7-12.
檢索: PubMed 16517412